ADC and Radiopharmaceuticals Pharma and Biotech Partnering Summit Revere Hotel Boston Common, Boston

Major moves in the pharma and biotech partnering are reshaping the landscape. With AbbVie’s acquisition of ImmunoGen leading the charge in 2023, and Merck’s licensing deal with Daiichi reaching unprecedented heights across three ADC programs, the market frenzy surrounding ADCs has never been hotter.

Even Eli Lilly’s acquisition of Mablink, despite lacking clinical programs, underscores the feverish pace of activity in the field, breaking traditional pharma partnering trends.

For ADC companies, the challenge lies in standing out, validating their offerings, and securing clinical-ready assets amidst this whirlwind of activity.